Pesquisa | BVS Doenças Infecciosas e Parasitárias

1.

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.

Basu, B; Krebs, M G; Sundar, R; Wilson, R H; Spicer, J; Jones, R; Brada, M; Talbot, D C; Steele, N; Ingles Garces, A H; Brugger, W; Harrington, E A; Evans, J; Hall, E; Tovey, H; de Oliveira, F M; Carreira, S; Swales, K; Ruddle, R; Raynaud, F I; Purchase, B; Dawes, J C; Parmar, M; Turner, A J; Tunariu, N; Banerjee, S; de Bono, J S; Banerji, U.

Ann Oncol ; 29(9): 1918-1925, 2018 09 01.

Artigo em Inglês | MEDLINE | ID: mdl-30016392

2.

[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]. / Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib.

Griesinger, F; Radke, S; Lüers, A; Deschler-Baier, B; Kimmich, M; Sebastian, M; Schulz, C; Brugger, W; Wiewrodt, R; Pirker, R; Früh, M; Gautschi, O; Wolf, J.

Pneumologie ; 72(11): 774-781, 2018 Nov.

Artigo em Alemão | MEDLINE | ID: mdl-30408830

3.

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).

Rummel, M; Kim, T M; Aversa, F; Brugger, W; Capochiani, E; Plenteda, C; Re, F; Trask, P; Osborne, S; Smith, R; Grigg, A.

Ann Oncol ; 28(4): 836-842, 2017 04 01.

Artigo em Inglês | MEDLINE | ID: mdl-28031173

4.

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

Coudert, B; Ciuleanu, T; Park, K; Wu, Y-L; Giaccone, G; Brugger, W; Gopalakrishna, P; Cappuzzo, F.

Ann Oncol ; 23(2): 388-94, 2012 Feb.

Artigo em Inglês | MEDLINE | ID: mdl-21610154

5.

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.

Stemmler, H J; diGioia, D; Freier, W; Tessen, H W; Gitsch, G; Jonat, W; Brugger, W; Kettner, E; Abenhardt, W; Tesch, H; Hurtz, H J; Rösel, S; Brudler, O; Heinemann, V.

Br J Cancer ; 104(7): 1071-8, 2011 Mar 29.

Artigo em Inglês | MEDLINE | ID: mdl-21407218

6.

Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).

Faehling, M; Achenbach, J; Staib, P; Steffen, U; Tessen, H W; Gaillard, V E; Brugger, W.

J Cancer Res Clin Oncol ; 144(7): 1375-1383, 2018 Jul.

Artigo em Inglês | MEDLINE | ID: mdl-29687154

7.

Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.

Romieu, G; Clemens, M; Mahlberg, R; Fargeot, P; Constenla, M; Schütte, M; Easton, V; Skacel, T; Bacon, P; Brugger, W.

Crit Rev Oncol Hematol ; 64(1): 64-72, 2007 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-17317205

8.

The fascinating life of hematopoietic stem cells.

Sharkis, S; Kanz, L; Brugger, W; Orlic, D.

Nat Med ; 4(10): 1118-9, 1998 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-9771737

9.

Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells.

Brossart, P; Zobywalski, A; Grünebach, F; Behnke, L; Stuhler, G; Reichardt, V L; Kanz, L; Brugger, W.

Cancer Res ; 60(16): 4485-92, 2000 Aug 15.

Artigo em Inglês | MEDLINE | ID: mdl-10969796

10.

Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.

Brossart, P; Stuhler, G; Flad, T; Stevanovic, S; Rammensee, H G; Kanz, L; Brugger, W.

Cancer Res ; 58(4): 732-6, 1998 Feb 15.

Artigo em Inglês | MEDLINE | ID: mdl-9485028

11.

Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy.

Andreesen, R; Scheibenbogen, C; Brugger, W; Krause, S; Meerpohl, H G; Leser, H G; Engler, H; Löhr, G W.

Cancer Res ; 50(23): 7450-6, 1990 Dec 01.

Artigo em Inglês | MEDLINE | ID: mdl-1701343

12.

The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.

Brossart, P; Schneider, A; Dill, P; Schammann, T; Grünebach, F; Wirths, S; Kanz, L; Bühring, H J; Brugger, W.

Cancer Res ; 61(18): 6846-50, 2001 Sep 15.

Artigo em Inglês | MEDLINE | ID: mdl-11559560

13.

Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.

Brugger, W; Frisch, J; Schulz, G; Pressler, K; Mertelsmann, R; Kanz, L.

J Clin Oncol ; 10(9): 1452-9, 1992 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-1517788

14.

Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells.

Brugger, W; Bühring, H J; Grünebach, F; Vogel, W; Kaul, S; Müller, R; Brümmendorf, T H; Ziegler, B L; Rappold, I; Brossart, P; Scheding, S; Kanz, L.

J Clin Oncol ; 17(5): 1535-44, 1999 May.

Artigo em Inglês | MEDLINE | ID: mdl-10334541

15.

Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients.

Viens, P; Chabannon, C; Pouillard, P; Janvier, M; Brugger, W; Blay, J Y; Oberling, F; Capdeville, R; Newman, C; Méresse, V; Xu, Z X; Platzer, E; Van der Auwera, P; Maraninchi, D.

J Clin Oncol ; 20(1): 24-36, 2002 Jan 01.

Artigo em Inglês | MEDLINE | ID: mdl-11773150

16.

A new look at the role of p53 in leukemia cell sensitivity to chemotherapy.

Trepel, M; Scheding, S; Groscurth, P; Horny, H P; Malipiero, U; Brugger, W; Dichgans, J; Weller, M.

Leukemia ; 11(11): 1842-9, 1997 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-9369416

17.

Macrophage colony-stimulating factor is required for human monocyte survival and acts as a cofactor for their terminal differentiation to macrophages in vitro.

Brugger, W; Kreutz, M; Andreesen, R.

J Leukoc Biol ; 49(5): 483-8, 1991 May.

Artigo em Inglês | MEDLINE | ID: mdl-2016569

18.

Surface phenotype analysis of human monocyte to macrophage maturation.

Andreesen, R; Brugger, W; Scheibenbogen, C; Kreutz, M; Leser, H G; Rehm, A; Löhr, G W.

J Leukoc Biol ; 47(6): 490-7, 1990 Jun.

Artigo em Inglês | MEDLINE | ID: mdl-1693647

19.

Dendritic cells in cancer vaccines.

Brossart, P; Wirths, S; Brugger, W; Kanz, L.

Exp Hematol ; 29(11): 1247-55, 2001 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-11698120

20.

How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after peripheral blood progenitor cell transplantation? Results of a computer simulation.

Scheding, S; Franke, H; Diehl, V; Wichmann, H E; Brugger, W; Kanz, L; Schmitz, S.

Exp Hematol ; 27(5): 956-65, 1999 May.

Artigo em Inglês | MEDLINE | ID: mdl-10340412

BVS Doenças Infecciosas e Parasitárias

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar: